Published Monday, July 20, 2020 9:54AM EDT https://www.ctvnews.ca/health/coronavirus/u-k-coronavirus-vaccine-prompts-immune-response-in-early-test-1.5031017 LONDON -- Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. “We are seeing good immune response in almost everybody,” said Dr. Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is trigger both arms of the immune system,” Hill said that neutralizing antibodies are produced — molecules which are key to blocking infection. In addition, the vaccine also causes a reaction in the body’s T-cells which help to fight off the coronavirus. He said that larger trials evaluating the vaccine’s effectiveness, involving about 10,000 people in the U.K. as well as participants in South Africa and Brazil are still underway. Another big trial is slated to start in the U.S. soon, aiming to enroll about 30,000 people. How quickly scientists are able to determine the vaccine’s effectiveness will depend largely on how much more transmission there is, but Hill estimated they might have sufficient data by the end of the year to decide if the vaccine should be adopted for mass vaccination campaigns. He said the vaccine seemed to produce a comparable level of antibodies to those produced by people who recovered from a COVID-19 infection and hoped that the T-cell response would provide extra protection. “There’s increasing evidence that having a T-cell response as well as antibodies could be very important in controlling COVID-19,” Hill said. He suggested the immune response might be boosted after a second dose; their trial tested two doses administered about four weeks apart. Hill said Oxford’s vaccine is designed to reduce disease and transmission. It uses a harmless virus — a chimpanzee cold virus, engineered so it can’t spread — to carry the coronavirus’ spike protein into the body, which should trigger an immune system response. Hill said Oxford has partnered with drugmaker AstraZeneca to produce their vaccine globally, and that the company has already committed to making 2 billion doses.
"It uses a harmless virus — a chimpanzee cold virus, engineered so it can’t spread — to carry the coronavirus’ spike protein into the body, which should trigger an immune system response." 未来可期，赞叹这种思路。
LONDON -- Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot.
“We are seeing good immune response in almost everybody,” said Dr. Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is trigger both arms of the immune system,”
Hill said that neutralizing antibodies are produced — molecules which are key to blocking infection. In addition, the vaccine also causes a reaction in the body’s T-cells which help to fight off the coronavirus.
He said that larger trials evaluating the vaccine’s effectiveness, involving about 10,000 people in the U.K. as well as participants in South Africa and Brazil are still underway. Another big trial is slated to start in the U.S. soon, aiming to enroll about 30,000 people.
How quickly scientists are able to determine the vaccine’s effectiveness will depend largely on how much more transmission there is, but Hill estimated they might have sufficient data by the end of the year to decide if the vaccine should be adopted for mass vaccination campaigns.
He said the vaccine seemed to produce a comparable level of antibodies to those produced by people who recovered from a COVID-19 infection and hoped that the T-cell response would provide extra protection.
“There’s increasing evidence that having a T-cell response as well as antibodies could be very important in controlling COVID-19,” Hill said. He suggested the immune response might be boosted after a second dose; their trial tested two doses administered about four weeks apart.
Hill said Oxford’s vaccine is designed to reduce disease and transmission. It uses a harmless virus — a chimpanzee cold virus, engineered so it can’t spread — to carry the coronavirus’ spike protein into the body, which should trigger an immune system response.
Hill said Oxford has partnered with drugmaker AstraZeneca to produce their vaccine globally, and that the company has already committed to making 2 billion doses.
“It is engineered so it can’t spread ”， so, it could be engineered to spread! Sound familiar?
什么意思？
（德国之声中文网）世界卫生组织的疫苗项目目录变得越来越长，仍旧不断有新的疫苗项目被收录在内。这项目录显示，目前全球范围内正在开始的新冠疫苗已经超过160种，其中大多数仍出于实验室或动物试验阶段。不过，大约23种疫苗则已经进入人体试验阶段。那么，哪一种疫苗会率先投入使用呢？
于贝拉（Klaus Überla）是艾尔朗根大学的病毒学家，同时也是德国疫苗委员会成员。他表示，哪一种疫苗最终将胜出，目前尚无法预言。但可喜的是，正如慕尼黑技术大学的普罗策教授（Ulrike Protzer)所言，目前已经有3种疫苗进入了第三阶段。她说："第三阶段就是最后一阶段的临床试验。"但该阶段也是疫苗试验中最复杂和最昂贵的环节。普罗策教授说，这一阶段通常会持续两年。现在因疫情紧迫，各方正在努力加快进度，比如让尽可能多的志愿者同时参与试验。 牛津团队目前领先 全球范围内，率先于今年五月进入第三阶段的疫苗是由牛津大学团队和制药公司AstraZeneca共同研发的。目前正在英国、南非和巴西对数千名志愿者开展人体试验，测试其抵抗新冠病毒的功效。下一步还将在美国等国对大约3万人开展接种试验。 AstraZeneca公司一名女发言人对北德电台表示："我们希望，今年秋季就能获得大规模人体试验的结果。"
德国紧追 德国已经有两种疫苗进入了临床试验阶段。图宾根CureVac公司前不久已开始了第一阶段试验，共有168名自愿者在图宾根、慕尼黑、汉诺威以及比利时的根特等地接受了疫苗注射。今年秋季，该公司将开启第二阶段试验。 美因茨的BioNTech公司进展则更快。该公司今年四月就获得了主管机构保罗艾里希研究所（ Paul-Ehrlich-Institut）在德国开展疫苗试验的许可。此外，该公司还同美国的制药巨头辉瑞计划有8000人参与的疫苗试验。此后，还将开展下一步涉及3万人的试验。BioNTech公司称，大规模疫苗试验七月底就有望在欧美开始进行。7月20日，有媒体报道称，英国方面已经向Bio Ntech 和法国一家公司预定了9000万剂新冠疫苗。 相比之下，另一家德国传染病研究中心的研发进度就慢了很多。该机构计划于今年球季开始人体疫苗试验，比其他竞争对手晚了大约半年。参与该研发项目的汉堡大学医学院传染病专家阿多（ Marylyn Addo）称，疫苗何时能投放市场，目前还很难说。 她表示，总体上，英国牛津大学团队和美国Moderna公司进展很快，七月份就可能开始最后阶段的临床试验；德国企业CureVac和BioNTech进度也很好。
可能是因为结论还不够清晰，市场不买账
好消息，谢分享
2020年7月21日13:20 CST 更新 https://cn.wsj.com/articles/牛津大学与阿斯利康合作研发的领先新冠候选疫苗试验结果正面-11595288707
周一，三种全球领先的候选疫苗均公布了积极的初步试验数据，提升了最早在今年成功开发出新冠疫苗的前景。
这三种候选疫苗分别是牛津大学(University of Oxford)研究人员和阿斯利康(AstraZeneca PLC, AZN)合作研发的疫苗、辉瑞公司(Pfizer Inc., PFE)及其德国合作伙伴BioNTech SE (BNTX)开发的疫苗、以及中国的康希诺生物股份公司(CanSino Biologics Inc., 6185.HK)研发的疫苗。三者均公布了最新的数据，显示接种之后产生了免疫应答，且具安全性。